SCHEMBL1593889

SCHEMBL1593889

COCCNC(=O)c1nc(C)c2cc(Cc3ccc(F)cc3)cnc2c1OCc1ccccc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLA2G2A P14555 1/20 0.40
LMNA P02545 5/20 0.38
KDM4E B2RXH2 4/20 0.38
HSD17B10 Q99714 1/20 0.38
TP53 P04637 1/20 0.38
MAPT P10636 2/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
PRSS1 P07477 1/20 0.37
PRSS2 P07478 1/20 0.37
PRSS3 P35030 1/20 0.37
TPSAB1 Q15661 1/20 0.37
HCRTR1 O43613 1/20 0.37
MAPK1 P28482 2/20 0.36
GAA P10253 1/20 0.36
SENP5 Q96HI0 1/20 0.36
SENP2 Q9HC62 1/20 0.36
SENP1 Q9P0U3 1/20 0.36
ALDH1A1 P00352 1/20 0.36
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13851001 0.92 MEN1 (0.40) PLA2G2ALMNAKDM4EHSD17B10MAPT
SCHEMBL1593189 0.92 LMNA (0.38) PLA2G2ALMNAKDM4EHSD17B10MAPT
SCHEMBL1593457 0.92 LMNA (0.38) PLA2G2ALMNAKDM4EHSD17B10MAPT
SCHEMBL1593191 0.91 PLA2G2A (0.39) PLA2G2ALMNAKDM4EHSD17B10TP53
SCHEMBL13851406 0.91 TP53 (0.38) PLA2G2ALMNAKDM4EHSD17B10TP53
SCHEMBL1593421 0.89 BRD4 (0.37) LMNAMAPTL3MBTL1MAPK1SENP5
SCHEMBL12703428 0.89 LMNA (0.40) PLA2G2ALMNAKDM4EHSD17B10MAPT
SCHEMBL12703471 0.89 LMNA (0.36) PLA2G2ALMNAKDM4EHSD17B10MAPT
SCHEMBL1593177 0.88 LMNA (0.36) PLA2G2ALMNAKDM4EHSD17B10TP53
SCHEMBL12703877 0.88 PLA2G2A (0.46) PLA2G2ALMNAHSD17B10TP53MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7919623-B2 Naphthyridine derivatives having inhibitory activity against HIV integrase SHIONOGI & CO., LTD. (JP) 2011-04-05 US disclosed
US-7919623-B2 Naphthyridine derivatives having inhibitory activity against HIV integrase SHIONOGI & CO., LTD. (JP) 2011-04-05 US disclosed
US-7919623-B2 Naphthyridine derivatives having inhibitory activity against HIV integrase SHIONOGI & CO., LTD. (JP) 2011-04-05 US disclosed
US-20090227621-A1 Naphthyridine derivatives having inhibitory activity against hiv integrase SHIONOGI & CO., LTD. (JP) 2009-09-10 US disclosed
US-20090227621-A1 Naphthyridine derivatives having inhibitory activity against hiv integrase SHIONOGI & CO., LTD. (JP) 2009-09-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090227621-A1 Naphthyridine derivatives having inhibitory activity against hiv integrase PNP, CDKL1, ASNS PLA2G2A 3862/4885LMNA 1421/4885KDM4E 1068/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.